(IN BRIEF) Sanofi has finalized its takeover of Vigil Neuroscience for roughly $470 million, acquiring all outstanding shares at $8 each and issuing a $2-per-share CVR tied to VG-3927’s first commercial sale. This deal, following Sanofi’s June 2024 strategic investment, … Read the full press release →
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged acquisition, Alzheimer’s disease, contingent value right, CVR, neurodegenerative research, Neurology, partnership, Phase 2 clinical study, preclinical pipeline, Sanofi, strategic investment, TREM2 agonist, VG-3927, VGL101, Vigil Neuroscience